Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Amicus Therapeutics, Inc.

Biotech R&D: BioMarin vs. Amicus - A Decade of Investment

__timestampAmicus Therapeutics, Inc.BioMarin Pharmaceutical Inc.
Wednesday, January 1, 201447624000461543000
Thursday, January 1, 201576943000634806000
Friday, January 1, 2016104793000661905000
Sunday, January 1, 2017149310000610753000
Monday, January 1, 2018270902000696328000
Tuesday, January 1, 2019286378000715007000
Wednesday, January 1, 2020308443000628116000
Friday, January 1, 2021272049000628793000
Saturday, January 1, 2022276677000649606000
Sunday, January 1, 2023152381000746773000
Monday, January 1, 2024747184000
Loading chart...

Igniting the spark of knowledge

A Decade of Innovation: R&D Spending in Biotech

In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, BioMarin Pharmaceutical Inc. and Amicus Therapeutics, Inc. have demonstrated contrasting strategies in their R&D investments.

BioMarin's Steady Growth

BioMarin has consistently invested in R&D, with expenses peaking in 2023 at approximately $747 million, marking a 62% increase from 2014. This steady growth underscores BioMarin's dedication to advancing its pipeline of therapies.

Amicus's Fluctuating Focus

Conversely, Amicus Therapeutics has shown more variability in its R&D spending. After a significant rise to $308 million in 2020, expenses dropped by 50% in 2023. This fluctuation may reflect strategic shifts or financial constraints.

Conclusion

These trends highlight the dynamic nature of R&D investment in the biotech sector, where strategic decisions can significantly impact a company's innovation trajectory.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025